Meta-analysis of the association between new hypoglycemic agents and digestive diseases
New hypoglycemic agents include sodium-glucose cotransporter-2 inhibitors (SGLT2is), glucagon-like peptide 1 receptor agonists (GLP1RAs), and dipeptidyl peptidase-4 inhibitors (DPP4is). The association between each class of these new hypoglycemic drugs and the risks of various digestive system disea...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2022-08, Vol.101 (34), p.e30072-e30072 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e30072 |
|---|---|
| container_issue | 34 |
| container_start_page | e30072 |
| container_title | Medicine (Baltimore) |
| container_volume | 101 |
| creator | Wang, Yu-Wen Lin, Jin-Hao Yang, Cui-Shan |
| description | New hypoglycemic agents include sodium-glucose cotransporter-2 inhibitors (SGLT2is), glucagon-like peptide 1 receptor agonists (GLP1RAs), and dipeptidyl peptidase-4 inhibitors (DPP4is). The association between each class of these new hypoglycemic drugs and the risks of various digestive system diseases is unknown. We aimed to explore this relationship by performing a meta-analysis. |
| doi_str_mv | 10.1097/MD.0000000000030072 |
| format | Article |
| fullrecord | <record><control><sourceid>wolterskluwer_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9410596</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>00005792-202208260-00087</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4277-a0fa9c81afab8f95bf8bd9967d28e6af689fd9f9b3ba8088b54a05f4e51473fb3</originalsourceid><addsrcrecordid>eNpdkMtOwzAQRS0Eory-gI1_IODYjh8bJFSeEhUbEEtrnIwbQ5pUcaDq3xMo4jWbuZqZezU6hBzn7CRnVp_OLk7YTwnGNN8ie3khVFZYJbd_6QnZT-mZsVxoLnfJRCgmuVJmjzzNcIAMWmjWKSbaBTrUSCGlrowwxK6lHocVYktbXNF6vezmzbrERSwpzLEdEoW2olWcYxriG44qISRMh2QnQJPw6KsfkMery4fpTXZ3f307Pb_LSsm1zoAFsKXJIYA3wRY-GF9Zq3TFDSoIythQ2WC98GCYMb6QwIogscilFsGLA3K2yV2--gVW5fhSD41b9nEB_dp1EN3fTRtrN-_enJU5G9GMAWITUPZdSj2Gb2_O3AdnN7tw_zmPLrlxrbpmwD69NK8r7F2N0Az153mhLc8445wZrlg2TowW78Ligbo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Meta-analysis of the association between new hypoglycemic agents and digestive diseases</title><source>Wolters Kluwer Open Health</source><source>DOAJ Directory of Open Access Journals</source><source>IngentaConnect Free/Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Wang, Yu-Wen ; Lin, Jin-Hao ; Yang, Cui-Shan</creator><creatorcontrib>Wang, Yu-Wen ; Lin, Jin-Hao ; Yang, Cui-Shan</creatorcontrib><description>New hypoglycemic agents include sodium-glucose cotransporter-2 inhibitors (SGLT2is), glucagon-like peptide 1 receptor agonists (GLP1RAs), and dipeptidyl peptidase-4 inhibitors (DPP4is). The association between each class of these new hypoglycemic drugs and the risks of various digestive system diseases is unknown. We aimed to explore this relationship by performing a meta-analysis.</description><identifier>ISSN: 1536-5964</identifier><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000030072</identifier><identifier>PMID: 36042668</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Systematic Review and Meta-Analysis</subject><ispartof>Medicine (Baltimore), 2022-08, Vol.101 (34), p.e30072-e30072</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4277-a0fa9c81afab8f95bf8bd9967d28e6af689fd9f9b3ba8088b54a05f4e51473fb3</citedby><cites>FETCH-LOGICAL-c4277-a0fa9c81afab8f95bf8bd9967d28e6af689fd9f9b3ba8088b54a05f4e51473fb3</cites><orcidid>0000-0002-5755-4229</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410596/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410596/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Wang, Yu-Wen</creatorcontrib><creatorcontrib>Lin, Jin-Hao</creatorcontrib><creatorcontrib>Yang, Cui-Shan</creatorcontrib><title>Meta-analysis of the association between new hypoglycemic agents and digestive diseases</title><title>Medicine (Baltimore)</title><description>New hypoglycemic agents include sodium-glucose cotransporter-2 inhibitors (SGLT2is), glucagon-like peptide 1 receptor agonists (GLP1RAs), and dipeptidyl peptidase-4 inhibitors (DPP4is). The association between each class of these new hypoglycemic drugs and the risks of various digestive system diseases is unknown. We aimed to explore this relationship by performing a meta-analysis.</description><subject>Systematic Review and Meta-Analysis</subject><issn>1536-5964</issn><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpdkMtOwzAQRS0Eory-gI1_IODYjh8bJFSeEhUbEEtrnIwbQ5pUcaDq3xMo4jWbuZqZezU6hBzn7CRnVp_OLk7YTwnGNN8ie3khVFZYJbd_6QnZT-mZsVxoLnfJRCgmuVJmjzzNcIAMWmjWKSbaBTrUSCGlrowwxK6lHocVYktbXNF6vezmzbrERSwpzLEdEoW2olWcYxriG44qISRMh2QnQJPw6KsfkMery4fpTXZ3f307Pb_LSsm1zoAFsKXJIYA3wRY-GF9Zq3TFDSoIythQ2WC98GCYMb6QwIogscilFsGLA3K2yV2--gVW5fhSD41b9nEB_dp1EN3fTRtrN-_enJU5G9GMAWITUPZdSj2Gb2_O3AdnN7tw_zmPLrlxrbpmwD69NK8r7F2N0Az153mhLc8445wZrlg2TowW78Ligbo</recordid><startdate>20220826</startdate><enddate>20220826</enddate><creator>Wang, Yu-Wen</creator><creator>Lin, Jin-Hao</creator><creator>Yang, Cui-Shan</creator><general>Lippincott Williams & Wilkins</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5755-4229</orcidid></search><sort><creationdate>20220826</creationdate><title>Meta-analysis of the association between new hypoglycemic agents and digestive diseases</title><author>Wang, Yu-Wen ; Lin, Jin-Hao ; Yang, Cui-Shan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4277-a0fa9c81afab8f95bf8bd9967d28e6af689fd9f9b3ba8088b54a05f4e51473fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Systematic Review and Meta-Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Yu-Wen</creatorcontrib><creatorcontrib>Lin, Jin-Hao</creatorcontrib><creatorcontrib>Yang, Cui-Shan</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Yu-Wen</au><au>Lin, Jin-Hao</au><au>Yang, Cui-Shan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Meta-analysis of the association between new hypoglycemic agents and digestive diseases</atitle><jtitle>Medicine (Baltimore)</jtitle><date>2022-08-26</date><risdate>2022</risdate><volume>101</volume><issue>34</issue><spage>e30072</spage><epage>e30072</epage><pages>e30072-e30072</pages><issn>1536-5964</issn><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>New hypoglycemic agents include sodium-glucose cotransporter-2 inhibitors (SGLT2is), glucagon-like peptide 1 receptor agonists (GLP1RAs), and dipeptidyl peptidase-4 inhibitors (DPP4is). The association between each class of these new hypoglycemic drugs and the risks of various digestive system diseases is unknown. We aimed to explore this relationship by performing a meta-analysis.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>36042668</pmid><doi>10.1097/MD.0000000000030072</doi><orcidid>https://orcid.org/0000-0002-5755-4229</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1536-5964 |
| ispartof | Medicine (Baltimore), 2022-08, Vol.101 (34), p.e30072-e30072 |
| issn | 1536-5964 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9410596 |
| source | Wolters Kluwer Open Health; DOAJ Directory of Open Access Journals; IngentaConnect Free/Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Systematic Review and Meta-Analysis |
| title | Meta-analysis of the association between new hypoglycemic agents and digestive diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T15%3A56%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wolterskluwer_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Meta-analysis%20of%20the%20association%20between%20new%20hypoglycemic%20agents%20and%20digestive%20diseases&rft.jtitle=Medicine%20(Baltimore)&rft.au=Wang,%20Yu-Wen&rft.date=2022-08-26&rft.volume=101&rft.issue=34&rft.spage=e30072&rft.epage=e30072&rft.pages=e30072-e30072&rft.issn=1536-5964&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000030072&rft_dat=%3Cwolterskluwer_pubme%3E00005792-202208260-00087%3C/wolterskluwer_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/36042668&rfr_iscdi=true |